home / stock / ltrn / ltrn quote
Last: | $4.38 |
---|---|
Change Percent: | 0.93% |
Open: | $4.25 |
Close: | $4.38 |
High: | $4.57 |
Low: | $4.25 |
Volume: | 17,695 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$4.38 | $4.25 | $4.38 | $4.57 | $4.25 | 17,695 | 07-05-2024 |
$4.29 | $4.38 | $4.29 | $4.57 | $4.25 | 25,523 | 07-04-2024 |
$4.29 | $4.38 | $4.29 | $4.57 | $4.25 | 25,523 | 07-03-2024 |
$4.4 | $4.47 | $4.4 | $4.68 | $4.4 | 21,948 | 07-02-2024 |
$4.52 | $4.76 | $4.52 | $4.9 | $4.4 | 40,541 | 07-01-2024 |
$4.67 | $4.56 | $4.67 | $4.868 | $4.51 | 78,201 | 06-28-2024 |
$4.54 | $4.25 | $4.54 | $4.61 | $4.24 | 43,924 | 06-27-2024 |
$4.27 | $4 | $4.27 | $4.29 | $4 | 48,823 | 06-26-2024 |
$4.01 | $3.87 | $4.01 | $4.15 | $3.83 | 66,386 | 06-25-2024 |
$3.91 | $4.14 | $3.91 | $4.21 | $3.85 | 160,586 | 06-24-2024 |
$4.15 | $4.42 | $4.15 | $4.64 | $4.1 | 117,697 | 06-21-2024 |
$4.44 | $4.61 | $4.44 | $4.61 | $4.32 | 107,542 | 06-20-2024 |
$4.69 | $4.84 | $4.69 | $4.88 | $4.5801 | 105,336 | 06-19-2024 |
$4.69 | $4.84 | $4.69 | $4.88 | $4.5801 | 105,336 | 06-18-2024 |
$4.91 | $5.25 | $4.91 | $5.25 | $4.77 | 125,000 | 06-17-2024 |
$5.37 | $5.41 | $5.37 | $5.56 | $5.15 | 80,923 | 06-14-2024 |
$5.44 | $5.64 | $5.44 | $5.64 | $5.25 | 37,205 | 06-13-2024 |
$5.65 | $5.65 | $5.65 | $5.86 | $5.4437 | 59,518 | 06-12-2024 |
$5.59 | $5.29 | $5.59 | $5.66 | $5.26 | 116,569 | 06-11-2024 |
$5.4 | $5.55 | $5.4 | $5.635 | $5.25 | 159,527 | 06-10-2024 |
News, Short Squeeze, Breakout and More Instantly...
LP-284 is currently in a Phase 1 clinical trial, having been developed with guidance from Lantern’s AI platform, RADR ® , as a potential therapy for relapsed or refractory non-Hodgkin’s lymphoma and certain genomically defined sarcomas. LP-284 is the third molecule brou...
Active clinical trials across three AI-guided drug candidates with initial data and clinical readouts for LP-184 on-track for the second half of 2024. Obtained regulatory allowance to begin Phase 2 Harmonic™ clinical trial enrollment in Japan and Taiwan where approximately 30-35+% ...
XCE853 is Oregon Therapeutic’s first-in-class, and potentially best-in-class PDI inhibitor, exhibiting potent preclinical efficacy across multiple solid and hematological cancers, and is ready to advance to Investigational New Drug (IND)-enabling development. The AI-enabled collabo...